Did Nader say that it was May/June when they are going to meet with the FDA to establish justification for the dosage level. Which would mean no need for establishing receptor occupancy.

I think we may have receptor occupancy tests for at least part of the CD12 trial at the 700mg dose. Since receptor occupancy is simply amount of CCR5 vs. occupancy at a given dosage it might be possible to show receptor occupancy from those results if the COVID-19 CCR5 level is comparable or higher than HIV.